跳至主要内容
临床试验/ACTRN12619000891123
ACTRN12619000891123已完成3 期

The impact of continuous terlipressin infusion on muscle, nutrition, ascites and inflammation in end-stage liver disease

Austin Health0 个研究点目标入组 30 人开始时间: 2019年6月26日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Austin Health
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients able to give informed consent
  • Age > 18 years
  • Patients with cirrhosis
  • Clinically significant ascites despite diuretic use or those requiring large volume paracentesis
  • Handgrip strength below average for age and gender

排除标准

  • Patients who have not seen a dietician for counselling and education on the recommended high protein high energy diet, and salt restriction at least 3 months prior to the commencement of the study
  • Past history of vascular disease (coronary artery disease or significant other vascular disease)
  • Past intolerance of terlipressin
  • Other contraindications to terlipressin including severe congestive cardiac failure (NYHA class III or IV) and poorly controlled hypertension
  • Patient deemed unsuitable for the Hospital in the Home (HITH) program

研究者

发起方
Austin Health

相似试验